<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36497181</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>23</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Micro-RNAs Shuttled by Extracellular Vesicles Secreted from Mesenchymal Stem Cells Dampen Astrocyte Pathological Activation and Support Neuroprotection in In-Vitro Models of ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3923</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11233923</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no effective cure. Astrocytes display a toxic phenotype in ALS and contribute to motoneuron (MN) degeneration. Modulating astrocytes' neurotoxicity can reduce MN death. Our previous studies showed the beneficial effect of mesenchymal stem cell (MSC) administration in SOD1<sup>G93A</sup> ALS mice, but the mechanisms are still unclear. We postulated that the effects could be mediated by extracellular vesicles (EVs) secreted by MSCs. We investigated, by immunohistochemical, molecular, and in vitro functional analyses, the activity of MSC-derived EVs on the pathological phenotype and neurotoxicity of astrocytes isolated from the spinal cord of symptomatic SOD1<sup>G93A</sup> mice and human astrocytes (iAstrocytes) differentiated from inducible neural progenitor cells (iNPCs) of ALS patients. In vitro EV exposure rescued mouse and human ALS astrocytes' neurotoxicity towards MNs. EVs significantly dampened the pathological phenotype and neuroinflammation in SOD1<sup>G93A</sup> astrocytes. In iAstrocytes, exposure to EVs increased the antioxidant factor Nrf2 and reduced reactive oxygen species. We previously found nine miRNAs upregulated in MSC-derived EVs. Here, the transfection of SOD1<sup>G93A</sup> astrocytes with single miRNA mimics reduced astrocytes' activation and the expression of neuroinflammatory factors. Moreover, miR-466q and miR-467f mimics downregulate <i>Mapk11</i>, while miR-466m-5p and miR-466i-3p mimics promote the nuclear translocation of Nrf2. In iAstrocytes, transfection with miR-29b-3p mimic upregulated NQO1 antioxidant activity and reduced neurotoxicity towards MNs. MSC-derived EVs modulate astrocytes' reactive phenotype and neurotoxicity through anti-inflammatory and antioxidant-shuttled miRNAs, thus representing a therapeutic strategy in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Provenzano</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giunti</LastName><ForeName>Debora</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0673-2646</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo, 316132 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torazza</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parodi</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo, 316132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3966-9874</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), 56122 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usai</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biophysics, National Research Council (CNR), Via De Marini 6, 16149 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerlero de Rosbo</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TomaLab, Institute of Nanotechnology, National Research Council (CNR), Piazzale Aldo Moro 5, 0018 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milanese</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3384-0666</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uccelli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo, 316132 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraiuolo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9118-5714</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Giambattista</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>2018.AAI629 U730/SD/pv</GrantID><Agency>Fondazione Compagnia di San Paolo</Agency><Country/></Grant><Grant><GrantID>IS-BRC-1215-20017</GrantID><Agency>NIHR Sheffield Biomedical Research Centre</Agency><Country/></Grant><Grant><GrantID>Bonanno/Apr16/848-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult mice spinal cord astrocytes</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cell therapy</Keyword><Keyword MajorTopicYN="N">extracellular vesicles</Keyword><Keyword MajorTopicYN="N">iNPCs-derived human astrocytes</Keyword><Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36497181</ArticleId><ArticleId IdType="pmc">PMC9741322</ArticleId><ArticleId IdType="doi">10.3390/cells11233923</ArticleId><ArticleId IdType="pii">cells11233923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H.J. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell. 1995;80:687&#x2013;692. doi: 10.1016/0092-8674(95)90346-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90346-1</ArticleId><ArticleId IdType="pubmed">7889564</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A. Amyotrophic lateral sclerosis-Evolutionary and other perspectives. Muscle Nerve. 2009;40:297&#x2013;304. doi: 10.1002/mus.21404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21404</ArticleId><ArticleId IdType="pubmed">19609920</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Gendron T.F., Staff N.P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin. Proc. 2018;93:1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69 doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk A.E., Weishaupt J.H., Andersen P.M., Ludolph A.C., Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Medizinische Genet. 2018;30:252&#x2013;258. doi: 10.1007/s11825-018-0185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11825-018-0185-3</ArticleId><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley M.E., Baloh R.H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Hyeon S.J., Im H., Ryu H.H., Kim Y., Ryu H.H. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp. Neurobiol. 2016;25:233&#x2013;240. doi: 10.5607/en.2016.25.5.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2016.25.5.233</ArticleId><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffaele S., Boccazzi M., Fumagalli M. Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives. Cells. 2021;10:565. doi: 10.3390/cells10030565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030565</ArticleId><ArticleId IdType="pmc">PMC8000560</ArticleId><ArticleId IdType="pubmed">33807572</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C., Guillemaud O., Carrillo-de Sauvage M.-A. Questions and (some) answers on reactive astrocytes. Glia. 2019;67:2221&#x2013;2247. doi: 10.1002/glia.23687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23687</ArticleId><ArticleId IdType="pubmed">31429127</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C., Galea E., Lakatos A., O&#x2019;Callaghan J.P., Petzold G.C., Serrano-Pozo A., Steinh&#xe4;user C., Volterra A., Carmignoto G., Agarwal A., et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021;24:312&#x2013;325. doi: 10.1038/s41593-020-00783-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995;38:73&#x2013;84. doi: 10.1002/ana.410380114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Bogaert E., Dewil M., Hersmus N., Kiraly D., Scheveneels W., Bockx I., Braeken D., Verpoorten N., Verhoeven K., et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. USA. 2007;104:14825&#x2013;14830. doi: 10.1073/pnas.0705046104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705046104</ArticleId><ArticleId IdType="pmc">PMC1976195</ArticleId><ArticleId IdType="pubmed">17804792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C., Corcia P., Piver E., Devos D., Dangoumau A., Gouel F., Vourc&#x2019;h P., Emond P., Laumonnier F., Nadal-Desbarats L., et al. Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2016;53:6910&#x2013;6924. doi: 10.1007/s12035-015-9567-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9567-6</ArticleId><ArticleId IdType="pubmed">26666663</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B., Mavel S., Coque E., Patin F., Vourc&#x2019;h P., Marouillat S., Nadal-Desbarats L., Emond P., Corcia P., Andres C.R., et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia. 2017;65:592&#x2013;605. doi: 10.1002/glia.23114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23114</ArticleId><ArticleId IdType="pubmed">28139855</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Woof R., Francis L., Gatto N., Shaw A.C., Myszczynska M., Hemingway J., Coldicott I., Willcock A., et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142:3771&#x2013;3790. doi: 10.1093/brain/awz302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId><ArticleId IdType="pmc">PMC6906594</ArticleId><ArticleId IdType="pubmed">31647549</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A.P., Kouloura E., Gray E., Thompson A.G., Talbot K., et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142:586&#x2013;605. doi: 10.1093/brain/awy353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A., McAvoy K., Krishnamurthy K., Trotti D., Pasinelli P. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia. 2018;66:1016&#x2013;1033. doi: 10.1002/glia.23298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23298</ArticleId><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M., Vallarola A., Lidonnici D., Battaglia E., Gensano F., Spaltro G., Fiordaliso F., Corbelli A., Garetto S., Martini E., et al. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J. Neurochem. 2015;135:109&#x2013;124. doi: 10.1111/jnc.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13154</ArticleId><ArticleId IdType="pubmed">25940956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P., Rodriguez-Muela N., Klim J.R., de Boer A.S., Agrawal S., Sandoe J., Lopes C.S., Ogliari K.S., Williams L.A., Shear M., et al. Reactive Astrocytes Promote ALS-like Degeneration and Intracellular Protein Aggregation in Human Motor Neurons by Disrupting Autophagy through TGF-$&#x3b2;$1. Stem Cell Rep. 2017;9:667&#x2013;680. doi: 10.1016/j.stemcr.2017.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.06.008</ArticleId><ArticleId IdType="pmc">PMC5549875</ArticleId><ArticleId IdType="pubmed">28712846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas F., Gonzalez D., Cortes N., Ampuero E., Hern&#xe1;ndez D.E., Fritz E., Abarzua S., Martinez A., Elorza A.A., Alvarez A., et al. Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. Front. Cell. Neurosci. 2015;9:203. doi: 10.3389/fncel.2015.00203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00203</ArticleId><ArticleId IdType="pmc">PMC4460879</ArticleId><ArticleId IdType="pubmed">26106294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas F., Cortes N., Abarzua S., Dyrda A., van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front. Cell. Neurosci. 2014;8:24. doi: 10.3389/fncel.2014.00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00024</ArticleId><ArticleId IdType="pmc">PMC3916762</ArticleId><ArticleId IdType="pubmed">24570655</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M., Pozzi S., Tortarolo M., Fiordaliso F., Bisighini C., Pasetto L., Spaltro G., Lidonnici D., Gensano F., Battaglia E., et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: Implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J. Biol. Chem. 2013;288:15699&#x2013;15711. doi: 10.1074/jbc.M112.425066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.425066</ArticleId><ArticleId IdType="pmc">PMC3668729</ArticleId><ArticleId IdType="pubmed">23592792</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Eid L., Parent M., Soucy G., Bareil C., Riku Y., Kawai K., Takagi S., Yoshida M., Katsuno M., et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A., Myszczynska M.A., Castelli L.M., O&#x2019;Neill B., Kim Y., Talbot J., Nyberg S., Nyamali I., Heath P.R., Stopford M.J., et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626&#x2013;635. doi: 10.1016/j.ebiom.2018.11.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.11.067</ArticleId><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Cunha C., Nascimento F., Ribeiro J.A., Vaz A.R., Brites D. Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model. Mol. Neurobiol. 2019;56:2137&#x2013;2158. doi: 10.1007/s12035-018-1220-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1220-8</ArticleId><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;2012:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciervo Y., Ning K., Jun X., Shaw P.J., Mead R.J. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. Mol. Neurodegener. 2017;12:1&#x2013;22. doi: 10.1186/s13024-017-0227-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0227-3</ArticleId><ArticleId IdType="pmc">PMC5683324</ArticleId><ArticleId IdType="pubmed">29132389</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K.-W., Moon C., Kim H.Y., Oh S.-I., Park J., Lee J.H., Chang I.Y., Kim K.S., Kim S.H. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl. Med. 2015;4:590&#x2013;597. doi: 10.5966/sctm.2014-0212.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0212</ArticleId><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K.-W., Noh M.-Y., Kwon M.-S., Kim H.Y., Oh S.-I., Park J., Kim H.-J., Ki C.-S., Kim S.H. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann. Neurol. 2018;84:361&#x2013;373. doi: 10.1002/ana.25302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25302</ArticleId><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykov&#xe1; E., Rychmach P., Drahor&#xe1;dov&#xe1; I., Konr&#xe1;dov&#xe1; &#x160;., R&#x16f;&#x17e;i&#x10d;kov&#xe1; K., Vo&#x159;&#xed;&#x161;ek I., Forostyak S., Homola A., Bojar M. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial. Cell Transplant. 2017;26:647&#x2013;658. doi: 10.3727/096368916X693716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368916X693716</ArticleId><ArticleId IdType="pmc">PMC5661219</ArticleId><ArticleId IdType="pubmed">27938483</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff N.P., Madigan N.N., Morris J., Jentoft M., Sorenson E.J., Butler G., Gastineau D., Dietz A., Windebank A.J. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016;87:2230&#x2013;2234. doi: 10.1212/WNL.0000000000003359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003359</ArticleId><ArticleId IdType="pmc">PMC5123559</ArticleId><ArticleId IdType="pubmed">27784774</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A., Milanese M., Principato M.C., Morando S., Bonifacino T., Vergani L., Giunti D., Voci A., Carminati E., Giribaldi F., et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 2012;18:794&#x2013;804. doi: 10.2119/molmed.2011.00498.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2011.00498</ArticleId><ArticleId IdType="pmc">PMC3409288</ArticleId><ArticleId IdType="pubmed">22481270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendt M., Rezvani K., Shpall E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant. 2019;54:789&#x2013;792. doi: 10.1038/s41409-019-0616-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-019-0616-z</ArticleId><ArticleId IdType="pubmed">31431712</ArticleId></ArticleIdList></Reference><Reference><Citation>Coatti G.C., Beccari M.S., Ol&#xe1;vio T.R., Mitne-Neto M., Okamoto O.K., Zatz M. Stem cells for amyotrophic lateral sclerosis modeling and therapy: Myth or fact? Cytometry. A. 2015;87:197&#x2013;211. doi: 10.1002/cyto.a.22630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22630</ArticleId><ArticleId IdType="pubmed">25645594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R., Mariotti R., Blandini F., Istituto F., Nazionale N., Mondino C., Martin L.J., Cova L. Front. Res. Found. Vol. 11. Frontiers Research Foundation; 2017. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles; p. 80.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Maffioli E., Nonnis S., Angioni R., Santagata F., Cal&#xec; B., Zanotti L., Negri A., Viola A., Tedeschi G. Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines. J. Proteomics. 2017;166:115&#x2013;126. doi: 10.1016/j.jprot.2017.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2017.07.012</ArticleId><ArticleId IdType="pubmed">28739509</ArticleId></ArticleIdList></Reference><Reference><Citation>Phinney D.G., Di Giuseppe M., Njah J., Sala E., Shiva S., St Croix C.M., Stolz D.B., Watkins S.C., Di Y.P., Leikauf G.D., et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat. Commun. 2015;6:8472. doi: 10.1038/ncomms9472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9472</ArticleId><ArticleId IdType="pmc">PMC4598952</ArticleId><ArticleId IdType="pubmed">26442449</ArticleId></ArticleIdList></Reference><Reference><Citation>Giunti D., Marini C., Parodi B., Usai C., Milanese M., Bonanno G., Kerlero de Rosbo N., Uccelli A. Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. Sci. Rep. 2021;11:1&#x2013;17. doi: 10.1038/s41598-021-81039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81039-4</ArticleId><ArticleId IdType="pmc">PMC7814007</ArticleId><ArticleId IdType="pubmed">33462263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Bonifacino T., Fedele E., Rebosio C., Cattaneo L., Benfenati F., Usai C., Bonanno G. Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: A mechanism for the ex-cessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiol. Dis. 2015;74:314&#x2013;324. doi: 10.1016/j.nbd.2014.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.004</ArticleId><ArticleId IdType="pubmed">25497732</ArticleId></ArticleIdList></Reference><Reference><Citation>Benvenuto F., Ferrari S., Gerdoni E., Gualandi F., Frassoni F., Pistoia V., Mancardi G., Uccelli A. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells. 2007;25:1753&#x2013;1760. doi: 10.1634/stemcells.2007-0068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2007-0068</ArticleId><ArticleId IdType="pubmed">17395776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106:1755&#x2013;1761. doi: 10.1182/blood-2005-04-1496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-04-1496</ArticleId><ArticleId IdType="pubmed">15905186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigo T., Procaccini C., Ferrara G., Baranzini S., Oksenberg J.R., Matarese G., Diaspro A., Kerlero de Rosbo N., Uccelli A. IFN-&#x3b3; orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. J. Allergy Clin. Immunol. 2017;139:1667&#x2013;1676. doi: 10.1016/j.jaci.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.09.004</ArticleId><ArticleId IdType="pubmed">27670240</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., Aach J., Ansorge W., Ball C.A., Causton H.C., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 2001;29:365&#x2013;371. doi: 10.1038/ng1201-365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1201-365</ArticleId><ArticleId IdType="pubmed">11726920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianco F., Pravettoni E., Colombo A., Schenk U., M&#xf6;ller T., Matteoli M., Verderio C. Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J. Immunol. 2005;174:7268&#x2013;7277. doi: 10.4049/jimmunol.174.11.7268.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.7268</ArticleId><ArticleId IdType="pubmed">15905573</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluzzi S., Alloisio S., Zappettini S., Milanese M., Raiteri L., Nobile M., Bonanno G. Adult astroglia is competent for Na+/Ca2+ exchanger-operated exocytotic glutamate release triggered by mild depolarization. J. Neurochem. 2007;103:1196&#x2013;1207. doi: 10.1111/j.1471-4159.2007.04826.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04826.x</ArticleId><ArticleId IdType="pubmed">17935604</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C., Cossu V., Kumar M., Milanese M., Cortese K., Bruno S., Bellese G., Carta S., Zerbo R.A., Torazza C., et al. The Role of Endoplasmic Reticulum in the Differential Endurance against Redox Stress in Cortical and Spinal Astrocytes from the Newborn SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Antioxidants. 2021;10:1392. doi: 10.3390/antiox10091392.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10091392</ArticleId><ArticleId IdType="pmc">PMC8472526</ArticleId><ArticleId IdType="pubmed">34573024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe W., Van Den Bosch L., Robberecht W. Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Res. 1998;807:1&#x2013;10. doi: 10.1016/S0006-8993(98)00569-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(98)00569-1</ArticleId><ArticleId IdType="pubmed">9756982</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K., Ferraiuolo L., Miranda C.J., Likhite S., McElroy S., Renusch S., Ditsworth D., Lagier-Tourenne C., Smith R.A., Ravits J., et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl. Acad. Sci. USA. 2014;111:829&#x2013;832. doi: 10.1073/pnas.1314085111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1314085111</ArticleId><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford M.J., Allen S.P., Ferraiuolo L. A High-throughput and Pathophysiologically Relevant Astrocyte-motor Neuron Co-culture Assay for Amyotrophic Lateral Sclerosis Therapeutic Discovery. Bio-protocol. 2019;9:e3353. doi: 10.21769/BioProtoc.3353.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.3353</ArticleId><ArticleId IdType="pmc">PMC6774773</ArticleId><ArticleId IdType="pubmed">31579294</ArticleId></ArticleIdList></Reference><Reference><Citation>Manders E.M.M., Verbeek F.J., Aten J.A. Measurement of co-localization of objects in dual-colour confocal images. J. Microsc. 1993;169:375&#x2013;382. doi: 10.1111/j.1365-2818.1993.tb03313.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.1993.tb03313.x</ArticleId><ArticleId IdType="pubmed">33930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Costes S.V., Daelemans D., Cho E.H., Dobbin Z., Pavlakis G., Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 2004;86:3993&#x2013;4003. doi: 10.1529/biophysj.103.038422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.103.038422</ArticleId><ArticleId IdType="pmc">PMC1304300</ArticleId><ArticleId IdType="pubmed">15189895</ArticleId></ArticleIdList></Reference><Reference><Citation>Krampera M., Pasini A., Pizzolo G., Cosmi L., Romagnani S., Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr. Opin. Pharmacol. 2006;6:435&#x2013;441. doi: 10.1016/j.coph.2006.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2006.02.008</ArticleId><ArticleId IdType="pubmed">16777484</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninger F., Glat M.J., Offen D., Steiner I. Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Clin. Neurosci. 2016;26:75&#x2013;78. doi: 10.1016/j.jocn.2015.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.10.008</ArticleId><ArticleId IdType="pubmed">26602604</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996;139:27&#x2013;33. doi: 10.1016/0022-510X(96)00073-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmeister A.R., Marriott I. The Interleukin-10 Family of Cytokines and Their Role in the CNS. Front. Cell. Neurosci. 2018;12:458. doi: 10.3389/fncel.2018.00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00458</ArticleId><ArticleId IdType="pmc">PMC6277801</ArticleId><ArticleId IdType="pubmed">30542269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M.R., Johnson D.A., Sirkis D.W., Messing A., Johnson J.A. Neurobiology of Disease Nrf2 Activation in Astrocytes Protects against Neurodegeneration in Mouse Models of Familial Amyotrophic Lateral Sclerosis. J. Neurosci. 2008;28:13574&#x2013;13581. doi: 10.1523/JNEUROSCI.4099-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4099-08.2008</ArticleId><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter A.D., Van Eldik L.J. The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis. 2010;1:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377763</ArticleId><ArticleId IdType="pubmed">22720195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlknecht U., Will J., Varin A., Hoelzer D., Herbein G. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J. Immunol. 2004;173:3979&#x2013;3990. doi: 10.4049/jimmunol.173.6.3979.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.6.3979</ArticleId><ArticleId IdType="pubmed">15356147</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimold A.M., Kim J., Finberg R., Glimcher L.H. Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int. Immunol. 2001;13:241&#x2013;248. doi: 10.1093/intimm/13.2.241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/13.2.241</ArticleId><ArticleId IdType="pubmed">11157857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Guo J., Wei X., Niu C., Jia M., Li Q., Meng D. Bach1: Function, Regulation, and Involvement in Disease. Oxid. Med. Cell. Longev. 2018;2018:1347969. doi: 10.1155/2018/1347969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1347969</ArticleId><ArticleId IdType="pmc">PMC6189649</ArticleId><ArticleId IdType="pubmed">30370001</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., K&#xf6;rner S., Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurol. Res. Int. 2012;2012:878030. doi: 10.1155/2012/878030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurinna S., Sch&#xe4;fer M., Ostano P., Karouzakis E., Chiorino G., Bloch W., Bachmann A., Gay S., Garrod D., Lefort K., et al. A novel Nrf2-miR-29-desmocollin-2 axis regulates desmosome function in keratinocytes. Nat. Commun. 2014;5:5099. doi: 10.1038/ncomms6099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6099</ArticleId><ArticleId IdType="pubmed">25283360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127&#x2013;D131. doi: 10.1093/nar/gkz757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz757</ArticleId><ArticleId IdType="pmc">PMC6943051</ArticleId><ArticleId IdType="pubmed">31504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20:18. doi: 10.1186/s13059-019-1629-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1629-z</ArticleId><ArticleId IdType="pmc">PMC6341724</ArticleId><ArticleId IdType="pubmed">30670076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou M., Zuo X., Li C., Zhang Y., Teng Y. Mir-29b Regulates Oxidative Stress by Targeting SIRT1 in Ovarian Cancer Cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2017;43:1767&#x2013;1776. doi: 10.1159/000484063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484063</ArticleId><ArticleId IdType="pubmed">29050034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadanandan N., Lee J.-Y., Garbuzova-Davis S. Extracellular vesicle-based therapy for amyotrophic lateral sclerosis. Brain Circ. 2021;7:23. doi: 10.4103/bc.bc_9_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/bc.bc_9_21</ArticleId><ArticleId IdType="pmc">PMC8057104</ArticleId><ArticleId IdType="pubmed">34084973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R., Turano E., Scambi I., Busato A., Bontempi P., Virla F., Schiaffino L., Marzola P., Bonetti B., Mariotti R. ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS. Int. J. Mol. Sci. 2020;21:3651. doi: 10.3390/ijms21103651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103651</ArticleId><ArticleId IdType="pmc">PMC7279464</ArticleId><ArticleId IdType="pubmed">32455791</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa K.P., Rossi I., Abdullahi M., Ramirez M.I., Stratton D., Inal J.M. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2022:e1835. doi: 10.1002/wnan.1835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1835</ArticleId><ArticleId IdType="pubmed">35898167</ArticleId></ArticleIdList></Reference><Reference><Citation>Loch-Neckel G., Matos A.T., Vaz A.R., Brites D. Challenges in the Development of Drug Delivery Systems Based on Small Extracellular Vesicles for Therapy of Brain Diseases. Front. Pharmacol. 2022;13:839790. doi: 10.3389/fphar.2022.839790.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.839790</ArticleId><ArticleId IdType="pmc">PMC9002061</ArticleId><ArticleId IdType="pubmed">35422699</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Rong Y., Wang J., Zhou Z., Ge X., Ji C., Jiang D., Gong F., Li L., Chen J., et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization. J. Neuroinflammation. 2020;17:47. doi: 10.1186/s12974-020-1726-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-1726-7</ArticleId><ArticleId IdType="pmc">PMC7001326</ArticleId><ArticleId IdType="pubmed">32019561</ArticleId></ArticleIdList></Reference><Reference><Citation>Phinney D.G., Pittenger M.F. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017;35:851&#x2013;858. doi: 10.1002/stem.2575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2575</ArticleId><ArticleId IdType="pubmed">28294454</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney M.J., Zhao Y., Jin Y.S., Batrakova E. V Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes. Cells. 2020;9:1273. doi: 10.3390/cells9051273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051273</ArticleId><ArticleId IdType="pmc">PMC7290714</ArticleId><ArticleId IdType="pubmed">32443895</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Chen Z., Zhang M. Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases. J. Transl. Med. 2022;20:291. doi: 10.1186/s12967-022-03493-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03493-6</ArticleId><ArticleId IdType="pmc">PMC9235237</ArticleId><ArticleId IdType="pubmed">35761337</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C.M.A., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In Vivo Base Editing. Mol. Ther. 2020;28:1177&#x2013;1189. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Losurdo M., Pedrazzoli M., D&#x2019;Agostino C., Elia C.A., Massenzio F., Lonati E., Mauri M., Rizzi L., Molteni L., Bresciani E., et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer&#x2019;s disease. Stem Cells Transl. Med. 2020;9:1068&#x2013;1084. doi: 10.1002/sctm.19-0327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.19-0327</ArticleId><ArticleId IdType="pmc">PMC7445021</ArticleId><ArticleId IdType="pubmed">32496649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Huang M., Zheng M., Dai C., Song Q., Zhang Q., Li Q., Gu X., Chen H., Jiang G., et al. ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer&#x2019;s disease. J. Control. Release Off. J. Control. Release Soc. 2020;327:688&#x2013;702. doi: 10.1016/j.jconrel.2020.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.09.019</ArticleId><ArticleId IdType="pubmed">32931898</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Wu H., Jiang X., Dong Y., Zheng J., Gao J. New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm. Sin. B. 2022;12:3215&#x2013;3232. doi: 10.1016/j.apsb.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9366301</ArticleId><ArticleId IdType="pubmed">35967290</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Giribaldi F., Melone M., Bonifacino T., Musante I., Carminati E., Rossi P.I.A., Vergani L., Voci A., Conti F., et al. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2014;64:48&#x2013;59. doi: 10.1016/j.nbd.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.11.006</ArticleId><ArticleId IdType="pubmed">24361555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Cattaneo L., Gallia E., Puliti A., Melone M., Provenzano F., Bossi S., Musante I., Usai C., Conti F., et al. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2017;123:433&#x2013;445. doi: 10.1016/j.neuropharm.2017.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.06.020</ArticleId><ArticleId IdType="pubmed">28645622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Provenzano F., Gallia E., Ravera S., Torazza C., Bossi S., Ferrando S., Puliti A., Van Den Bosch L., Bonanno G., et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2019;129:79&#x2013;92. doi: 10.1016/j.nbd.2019.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.05.007</ArticleId><ArticleId IdType="pubmed">31102766</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese M., Bonifacino T., Torazza C., Provenzano F., Kumar M., Ravera S., Zerbo A.R., Frumento G., Balbi M., Nguyen T.P.N., et al. Blocking glutamate mGlu(5) receptors with the negative allosteric modulator CTEP improves disease course in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2021;178:3747&#x2013;3764. doi: 10.1111/bph.15515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15515</ArticleId><ArticleId IdType="pmc">PMC8457068</ArticleId><ArticleId IdType="pubmed">33931856</ArticleId></ArticleIdList></Reference><Reference><Citation>Percie du Sert N., Hurst V., Ahluwalia A., Alam S., Avey M.T., Baker M., Browne W.J., Clark A., Cuthill I.C., Dirnagl U., et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 2020;177:3617&#x2013;3624. doi: 10.1111/bph.15193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15193</ArticleId><ArticleId IdType="pmc">PMC7393194</ArticleId><ArticleId IdType="pubmed">32662519</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>